FDA approves second novel HIV drug

Till recently, just two classes of antiretroviral drugs, reverse transcriptase inhibitors and protease inhibitors, were on the market to treat HIV infection. Last week, the FDA linkurl:approved;http://www.reuters.com/article/health-SP/idUSN1221331120071015 Merck's raltegravir (Isentress), which interferes with viral replication at a different point, blocking the enzyme integrase to prevent the integration of the viral genetic material into host DNA. In our September issue, The Scientist reporte

By | October 16, 2007

Till recently, just two classes of antiretroviral drugs, reverse transcriptase inhibitors and protease inhibitors, were on the market to treat HIV infection. Last week, the FDA linkurl:approved;http://www.reuters.com/article/health-SP/idUSN1221331120071015 Merck's raltegravir (Isentress), which interferes with viral replication at a different point, blocking the enzyme integrase to prevent the integration of the viral genetic material into host DNA. In our September issue, The Scientist reported on Pfizer's linkurl:maraviroc,;http://www.the-scientist.com/2007/9/1/43/1/ approved in the US in August under the brand name Selzentry. While other HIV drugs work inside the cell, maraviroc blocks the activity of CCR5, the coreceptor on the cell surface that facilities HIV's entry into the cell. The two are the first compounds with a novel mechanism of action against the virus to be approved in several years. So far, both drugs are approved for use only in patients who have developed a resistance to other drugs.
Advertisement

Popular Now

  1. The Meaning of Pupil Dilation
    Daily News The Meaning of Pupil Dilation

    Scientists are using pupil measurements to study a wide range of psychological processes and to get a glimpse into the mind.

  2. Exercise-Induced Muscle Factor Promotes Memory
  3. Illustrating #FieldworkFails
  4. Transmissible Cancers Plague Mollusks
Biosearch Technologies